The COVID Project
The record
- Jurisdiction
- United States (federal); Drug Enforcement Administration, Diversion Control Division (with SAMHSA)
- Level
- Federal
- Authority
- 21 U.S.C. 802(54)(D), 823(g)(2); 21 C.F.R. 1301.28
- Issued
- 2020-03-31 Mar. 31, 2020
- Effective
- 2020-03-31
- End
- Until the public health emergency declared by the Secretary ends, unless DEA specifies an earlier date (extended by 88 Fed. Reg. 30037) (read as 2021-09-30)
- In force
- Mar. 31, 2020 to Sept. 30, 2021
- Quarters
- 2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
- Limitation types
- Telework mandateHealth care ordersOther
- Addressees
- DATA-waived practitioners
- opioid treatment programs
- Functions reached
- TM telehealth (audio-only induction)
- CL clinical intake
- CB patients
- Collection
- Other federal health agencies AGY-FED-HEALTH-OTHER
Operative words
This additional flexibility under which authorized practitioners may prescribe buprenorphine to new patients on the basis of a telephone evaluation is in effect from March 31, 2020, until the public health emergency declared by the Secretary ends, unless DEA specifies an earlier date.
Enforcement
Prescriptions outside the allowance unlawful under 21 U.S.C. 829(e), 841-843
Notes
Reached behavioral-health and addiction-treatment providers, FQHCs and telehealth companies.